Phathom Pharmaceuticals, Inc. EPS (Diluted, from Cont. Ops)

EPS (Diluted, from Cont. Ops) of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including EPS (Diluted, from Cont. Ops) growth rates and interactive chart.


Highlights and Quick Summary

  • EPS (Diluted, from Cont. Ops) for the quarter ending June 29, 2021 was $-0.998 (a 3.94% increase compared to previous quarter)
  • Year-over-year quarterly EPS (Diluted, from Cont. Ops) decreased by -2.39%
  • Annual EPS (Diluted, from Cont. Ops) for 2020 was $-3.88 (a -82.69% decrease from previous year)
  • Annual EPS (Diluted, from Cont. Ops) for 2019 was $-22.4 (a 10447.42% increase from previous year)
  • Twelve month EPS (Diluted, from Cont. Ops) ending June 29, 2021 was $-4.58 (a 8.48% increase compared to previous quarter)
  • Twelve month trailing EPS (Diluted, from Cont. Ops) increased by 115.02% year-over-year
Trailing EPS (Diluted, from Cont. Ops) for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$-4.58 $-4.22 $-3.88 $-2.13
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EPS (Diluted, from Cont. Ops) of Phathom Pharmaceuticals, Inc.

Most recent EPS (Diluted, from Cont. Ops)of PHAT including historical data for past 10 years.

Interactive Chart of EPS (Diluted, from Cont. Ops) of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. EPS (Diluted, from Cont. Ops) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.0 $0.0
2020 $0.0 $0.0 $0.0 $0.0 $0.0
2019 $0.0 $0.0 $0.0 $0.0 $0.0
2018 $0.0 $0.0

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.